Considering the fact that introduction of PD-(L)1 inhibitors a few years ago has already facilitated 5-year survival rates of 30–50% for patients with per se highly lethal neoplasms, such as metastatic melanoma and non-small-cell lung carcinoma [233,234], the upcoming complementation of current strategies with “next-generation” immunotherapeutics, such as multispecific antibodies and cell therapies, offers a justified hope for the cure of some advanced cancers in the near future. Here, CD274 is linked to non-small cell lung carcinoma.